Country Report: China
Pharmaceutical Executive
A decade into China’s far-reaching healthcare reforms-which began with the implementation of universal, albeit rudimentary, medical insurance-the pace of change and transformation within the country’s life sciences industry shows no signs of abating.
Let a Hundred Flowers Bloom
China's meteoric rise as an economic and political power on the global stage dominates discourse today. While the "Middle Kingdom" is reclaiming global attention, an equally remarkable story of transformation is coalescing within the country's healthcare and life sciences industry. A decade into China's far-reaching healthcare reforms, which began in 2009 with the implementation of universal, albeit rudimentary, medical insurance, the furious pace of change shows no signs of abating.
Since the State Council issued the Healthy China 2030 blueprint in October 2016, China has forged its own path toward the Holy Trinity of access, affordability, and innovation. A cascade of reforms and policies aimed at aligning China with the best practices of the global industry while accommodating the exceptional needs of the Chinese market is steadily shaping a new healthcare system with Chinese characteristics.
To view the full article on China's healthcare and life sciences markets, produced by Focus Reports and featured in Pharm Exec's September 2019 issue, click
here(cycle down to page 42).
To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
